Figure 2From: Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIsComparison of the plasma interleukin (IL)-8 levels before and after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. The IL-8 (5.48 pg/mL; range, 0.49–26.13 pg/mL) levels on treatment day 30 were significantly lower than levels at diagnosis (10.45 pg/mL; range, 3.04–54.86 pg/mL; P = .021).Back to article page